CP 380867

Drug Profile

CP 380867

Latest Information Update: 10 Feb 2003

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Class Antihyperglycaemics
  • Mechanism of Action Glycogen phosphorylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Reperfusion injury; Type 2 diabetes mellitus

Most Recent Events

  • 10 Feb 2003 No development reported - Preclinical for Reperfusion injury in USA (unspecified route)
  • 10 Feb 2003 No development reported - Preclinical for Type-2 diabetes mellitus in USA (unspecified route)
  • 31 Jul 2001 Preclinical development for Reperfusion injury in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top